Lack of effect of ischemia and dipyridamole on prostacyclin production in arteriosclerosis obliterans.
Six patients with advanced arteriosclerosis obliterans in the lower extremities were subjected to an exercise test on a tread mill with and without dipyridamole treatment. Prostacyclin (PGI2) release was measured by the concentration of its stable metabolite, 6-keto-prostaglandin F1 alpha in plasma. All the patients suffered from ischemic pain during both tests, but no changes were seen in plasma 6-keto-PGF1 alpha. Dipyridamole did not affect the physical performance. Our results suggest that atherosclerotic vessels do not increase PGI2 production in response to ischemia and that a single dose of dipyridamole does not change PGI2 production.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000378:metabolism*; D004176:Dipyridamole; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D007511:Ischemia / Q000209:etiology / Q000378:metabolism*; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D011453:Prostaglandins / Q000096:biosynthesis*
D011453:Prostaglandins; D015121:6-Ketoprostaglandin F1 alpha; D004176:Dipyridamole; D011464:Epoprostenol